Featured

Treatment-Resistant Depression: Augmentation with Second-Generation Antipsychotics (Aripiprazole vs Quetiapine)

Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation compares advantages and disadvantages of using quetiapine vs. aripiprazole as augmentation for treatment-resistant depression. It also addresses the common question of when to augment (antidepressant + SGA) vs. when to switch (prescribing a different antidepressant). Combination and Augmentation: Clarifying Concepts…

Read More

Inflammation and Depression: Use of Anti-Inflammatory Agents and The Role of Inflammatory Markers (CRP)

Prof. Philip Cowen Professor of Psychopharmacology Department of Psychiatry University of Oxford, UK This presentation summarizes recent findings on the role of inflammation in depression. A study suggests patients with elevated levels of inflammatory markers (C-reactive protein) have a differential response to a specific antidepressant. The efficacy of celecoxib and infliximab in treatment-resistant depression is…

Read More

2018 APA Alcohol Use Disorder Guideline: Summary of Recommendations

By Flavio Guzman, MD Editor Psychopharmacology Institute The American Psychiatric Association (APA) released a new practice guideline on the treatment of alcohol use disorder. We reproduce below a summary of selected recommendations on pharmacotherapy. Pharmacotherapies for Alcohol Use Disorder Naltrexone or Acamprosate APA recommends (1B) that naltrexone or acamprosate be offered to patients with moderate…

Read More

2017 in Review: New Drugs, Formulations and Clinical Guidelines

Author: Flavio Guzman, MD Dr. Guzman has no conflicts of interest to disclose. In this article, we look back at the most clinically relevant news of 2017 in the field of psychopharmacology. In terms of new drugs, two medications were approved for the treatment of tardive dyskinesia: valbenazine (Ingrezza) and  deutetrabenazine (Austedo). This publication also summarizes…

Read More

Cannabis: Currently Approved Indications and Therapeutic Potential

Dr. Paul Morrison Clinical Senior Lecturer Institute of Psychiatry King’s College London NHS Consultant Psychiatrist The Maudsley Hospital, London       This presentation reviews indications for currently approved cannabis products (dronabinol and nabilone). It also discusses the therapeutic potential of CBD in psychiatry (psychosis) and other medical conditions (epilepsy, oncology). In this section, we’ll…

Read More

Trazodone for Disturbed Sleep Initiation in PTSD

David N. Osser, MD Associate Professor of Psychiatry Harvard Medical School Brockton Division of the VA Boston Healthcare System In this video, Dr. David Osser reviews the evidence base for the use of trazodone in PTSD patients with disturbed sleep initiation. He also comments on side effects, with a focus on priapism. This video is…

Read More

Understanding Cannabis in Psychiatry: Pharmacology and Synthetic Cannabinoids

Dr. Paul Morrison   Clinical Senior Lecturer Institute of Psychiatry King’s College London   NHS Consultant Psychiatrist The Maudsley Hospital, London     This presentation discusses cannabinoid pharmacology and synthetic cannabinoids. The endocannabinoid system consists of: CB1 and CB2 receptors, anandamide, 2‐arachidonoylglycerol (2-AG). Regarding synthetic cannabinoids, they are CB1 full agonists and their effect is…

Read More

Antipsychotics News: Cariprazine, Risperidone and New Drug Applications

Author: Flavio Guzman, MD Editor Psychopharmacology Institute Dr. Guzman has no conflicts of interest to disclose. Cariprazine for Negative Symptoms of Schizophrenia: The FDA Refuses to Review Supplemental New Drug Application (sNDA) The FDA has refused Allergan’s request to review a Supplemental New Drug Application (sNDA) to expand the approved uses to include negative symptoms of schizophrenia…

Read More

Buprenorphine for Opioid Use Disorder: Mechanism of Action

By Joji Suzuki, MD Director, Division of Addiction Psychiatry Department of Psychiatry Brigham and Women’s Hospital Assistant Professor of Psychiatry Harvard Medical School This presentation reviews the mechanism of action of buprenorphine in the treatment of opioid use disorders. Dr. Suzuki explains how partial agonism and high affinity for mu opioid receptors increases the risk of…

Read More

Comments on the 2017 VA/DoD Practice Guideline for the Management of PTSD

By: David Osser, MD; Flavio Guzman, MD In June 2017, the U.S. Department of Veterans Affairs and the Department of Defense published a new edition of the Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. After we published a video lecture (Faculty: David Osser, MD , Harvard Medical School) on…

Read More